935517-11-6

Basic information

• Product Name: 2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzonitrile
• Synonyms: 2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzonitrile
• CAS NO: 935517-11-6
• Molecular Weight: 240.228
• Mol File: 935517-11-6.mol

Chemical Properties

• CAS DataBase Reference: 2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzonitrile(935517-11-6)
• EPA Substance Registry System: 2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzonitrile(935517-11-6)

Safety Data

• Hazardous Substances Data: 935517-11-6(Hazardous Substances Data)

Upstream product

• 123-75-1 pyrrolidine 
• 1813-33-8 2-chloro-4-trifluoromethyl-benzonitril 

Downstream Products

• 1338065-37-4 C₁₁H₁₁F₃N₂O 
• 1338064-84-8 1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea 
• 1341124-12-6 1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(2-oxoindolin-4-yl)urea 
• 1341124-11-5 1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(2-oxoindolin-4-yl)urea 
• 1338064-67-7 1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea 
• 1338064-41-7 1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea 
• 1338065-38-5 C₁₃H₁₃F₃N₂O 
• 1338064-85-9 1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b] [1,4]oxazin-8-yl)urea 
• 1338064-81-5 1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-5-yl)urea 
• 1338064-73-5 1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-7-yl)urea 
• 1338064-68-8 1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea 
• 1338064-42-8 1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea 
• 935518-11-9 (4-(trifluoromethyl)-2-(pyrrolidin-1-yl)phenyl)-methanamine 

Relevant articles and documents

Structure activity relationships of benzyl C-region analogs of 2-(3-fluoro-4-methylsulfonamidophenyl)propanamides as potent TRPV1 antagonists

A series of 2-substituted 4-(trifluoromethyl)benzyl C-region analogs of 2-(3-fluoro-4-methylsulfonamidophenyl)propanamides were investigated for hTRPV1 antagonism. The analysis indicated that the phenyl C-region derivatives exhibited better antagonism than those of the corresponding pyridine surrogates for most of the series examined. Among the phenyl C-region derivatives, the two best compounds 43 and 44S antagonized capsaicin selectively relative to their antagonism of other activators and showed excellent potencies with Ki(CAP) = 0.3 nM. These two compounds blocked capsaicin-induced hypothermia, consistent with TRPV1 as their site of action, and they demonstrated promising analgesic activities in a neuropathic pain model without hyperthermia. The docking study of 44S in our hTRPV1 homology model indicated that its binding mode was similar with that of its pyridine surrogate in the A- and B-regions but displayed a flipped configuration in the C-region.

"TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION"

The invention discloses compounds of formula I wherein Y is a group of formula A, B, C, D, or E: and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active

TRPV1 vanilloid receptor antagonists with a bicyclic portion

The invention discloses compounds of formula I wherein Y s selected from a group of formula and W, Q, n, R1, R2, R3, U1-U5 have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1. 1.

NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS

The present invention relates to novel vanilloid receptor ligands, to a process for the production thereof, to pharmaceutical preparations containing these compounds and to the use of these compounds for the production of pharmaceutical preparations.